Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06336304 · ClinicalTrials.gov registry record

NXT Post-Market Clinical Follow-up

A clinical trial of Urinary Incontinence and Urinary Incontinence, Urge, sponsored by Laborie Medical Technologies.

Recruiting
Registry status
180
Enrollment target
4
Study locations

NCT06336304 is a study of Urinary Incontinence and Urinary Incontinence, Urge that is actively recruiting participants, run by Laborie Medical Technologies. The registered enrollment target is 180 participants, below the 258-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (30% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06336304, a study of Urinary Incontinence and Urinary Incontinence, Urge, is actively recruiting participants, sponsored by Laborie Medical Technologies.

RECRUITING
Registry status
180 participants
Enrollment target
4
Study locations

Study Summary

NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations

Interventions

  • DIAGNOSTIC_TEST Urodynamic procedure

Study Locations (4)

Maryland

  • Chesapeake Urology Hanover - Hanover
  • Chesapeake Urology Owing Mills - Owing Mills

Ohio

  • Ohio State University - Columbus

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2024-06-18
Est. Completion 2025-12

Sponsor

Laborie Medical Technologies

5 total trials

What the Registry Record Tells You About NCT06336304

The ClinicalTrials.gov registry entry for NCT06336304 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 258-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (30% lower). The listed sponsor is Laborie Medical Technologies, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Urinary Incontinence appearing as the primary indexed condition, and to 1 intervention - of which Urodynamic procedure is the first listed.

NCT06336304 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Maryland, Ohio, Virginia.

Frequently Asked Questions

What is clinical trial NCT06336304 about?

NCT06336304 is a clinical study titled "NXT Post-Market Clinical Follow-up". NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations

What is the current status of trial NCT06336304?

This trial is currently recruiting. The enrollment target is 180 participants. The study started on 2024-06-18. Estimated completion is 2025-12.

What conditions does trial NCT06336304 study?

This clinical trial studies the following conditions: Urinary Incontinence, Urinary Incontinence, Urge, Urinary Bladder, Overactive, Urinary Bladder, Neurogenic, Urinary Obstruction.

What interventions are being tested in trial NCT06336304?

The interventions under investigation include: Urodynamic procedure (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06336304?

This trial is sponsored by Laborie Medical Technologies, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06336304 being conducted?

This trial has 4 study locations across Maryland, Ohio, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Urinary Incontinence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.